Craig C. Hopkinson - 03 Aug 2026 Form 4 Insider Report for Alkermes plc. (ALKS)

Reporting relationship: EVP R&D, Chief Medical Officer
Issuer ticker: ALKS
Reported as of: 03 Aug 2026
Net transaction value: -$437,220
SEC form: 4
Accepted by SEC: 03 Aug 2026, 19:12:58 UTC
Prior SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson

Key filing fact

Craig C. Hopkinson filed Form 4 for Alkermes plc. (ALKS) on 03 Aug 2026.

Key facts

This page summarizes Craig C. Hopkinson's Form 4 filing for Alkermes plc. (ALKS).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Aug 2026, 19:12.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: -$437,220.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730048 Primary reporting owner

Hopkinson Craig C.

Relationship: EVP R&D, Chief Medical Officer
Address: 900 WINTER STREET, WALTHAM
Signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Signature date: 03 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALKS transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +104
Change %: +0.14%
Price: $19.34^*
Shares after: 73,493
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1

ALKS transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +4,896
Change %: +6.7%
Price: $24.59^*
Shares after: 78,389
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1

ALKS transaction

Ordinary Shares

Sale

Transaction value: $437,220
Shares: -9,000
Change %: -11%
Price: $48.58
Shares after: 69,389
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALKS transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -104
Change %: -7.7%
Price: $0.000000^*
Shares after: 1,252
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 104
Exercise price: $19.34
Footnotes: F1, F3

ALKS transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -4,896
Change %: -6.9%
Price: $0.000000^*
Shares after: 66,276
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,896
Exercise price: $24.59
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

Footnote F2

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

Footnote F3

These options are fully vested in accordance with their terms.